TGFB1 and neoplasm: In a mouse model recapitulating this phenotype, co-treatment with TGF-β1-blockers and anti-PD-L1 antibodies helped T-cells penetrate into the tumor center, provoking substantial antitumor immunity and causing tumor shrinkage [17,18].